Stockreport

Evelo Biosciences Announces Positive Phase 2 Clinical Data with EDP1815 in Psoriasis; Confirms Ability to Harness the Small Intestinal Axis, SINTAX™, to Treat Systemic Inflammatory Disease

Evelo Biosciences, Inc.  (EVLO) 
Last evelo biosciences, inc. earnings: 2/13 07:00 am Check Earnings Report
PDF –Clinically and statistically significant improvement in PASI-50 score achieved––EDP1815 safety and tolerability data comparable to placebo in study––EDP1815 advancing t [Read more]